Peak Bio, Inc. (PKBO)
OTCMKTS
· Delayed Price · Currency is USD
0.180
+0.005 (2.86%)
At close: Sep 20, 2024
Peak Bio Company Description
Peak Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of patients with cancer, inflammatory, and rare diseases in the United States.
The company’s lead product candidate is PHP-303, which is in Phase 2 clinical study for the treatment of alpha-1 antitrypsin deficiency and acute respiratory distress syndrome.
It also develops Trop2 PH1, an antibody-drug-conjugate in preclinical trials for solid tumors. Peak Bio, Inc. is based in Pleasanton, California.
Peak Bio, Inc.
| Country | United States |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 6 |
Contact Details
Address: 4900 Hopyard Road Pleasanton, Delaware 94588 United States | |
| Phone | 925-463-4800 |
| Website | peak-bio.com |
Stock Details
| Ticker Symbol | PKBO |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| ISIN Number | US70470P1084 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Hoyoung Huh M.D., Ph.D. | Executive Chairman |
| Dr. Satyajit Mitra Ph.D. | Head of Oncology and Executive Director |
| Divya Patel | Controller and Treasurer |
| Moddy Wong | Director of Human Resources |